Carisma Therapeutics, Inc. (CARM) Total Return Calculator with Dividends Reinvested

Carisma Therapeutics, Inc.

Popular:

The total return for Carisma Therapeutics, Inc. (CARM) stock is -96.22% over the past 12 months. So far it's down 56.82% this year. The 5-year total return is -99.56%, meaning $10,000 invested in CARM stock 5 years ago would be worth $44 today. Total return includes price appreciation plus reinvesting any dividends paid out.

If you invested $10,000 in CARM 1 year ago, it would be worth $431 today — you'd have lost $9,569.

With Dividends Reinvested$431-95.69%

Price Only (No DRIP)$431-95.69%

Period2025-06-20 → 2026-06-18

Price

Total Return (DRIP)

S&P 500

If You Invested $10,000 in CARM

1Y$378-$9,622 (-96.2%)-96.2% CAGR

3Y$22-$9,978 (-99.8%)-87.0% CAGR

5Y$44-$9,956 (-99.6%)-66.3% CAGR

10Y$86-$9,914 (-99.1%)-37.9% CAGR

15Y$18-$9,982 (-99.8%)-34.5% CAGR

20Y$18-$9,982 (-99.8%)-27.2% CAGR

30Y$18-$9,982 (-99.8%)-19.1% CAGR

Carisma Therapeutics, Inc. did not pay dividends during this period. Total return = price return.

Loading CARM total return...

As of 2026-06-19

Returns at a Glance

Period	Total Return	CAGR	Price Only	Div. Contrib.	$10K →
YTD	-56.82%	—	-56.82%	—	$4,318
1Y	-96.22%	-96.22%	-96.22%	—	$378
3Y	-99.78%	-86.98%	-99.78%	—	$22
5Y	-99.56%	-66.27%	-99.98%	+0.41 pp	$44
10Y	-99.14%	-37.88%	-99.96%	+0.81 pp	$86
15Y	-99.82%	-34.50%	-99.99%	+0.17 pp	$18
20Y	-99.82%	-27.19%	-99.99%	+0.17 pp	$18
30Y	-99.82%	-19.07%	-99.99%	+0.17 pp	$18

Risk & Highlights

Best Year+71.08%2018

Worst Year-90.23%2025

Max Drawdown-99.98%2025-06-18 → 2026-05-14

Annual Returns

Year	Total Return	Price Return	Div.	S&P 500	vs S&P
2026YTD	-2.27%	-2.27%	—	+0.41%	-2.7pp
2025	-90.23%	-90.23%	—	+16.64%	-106.9pp
2024	-85.25%	-85.25%	—	+24.00%	-109.3pp
2023	-74.25%	-77.07%	+2.8pp	+24.81%	-99.1pp
2022	-28.76%	-28.76%	—	-19.95%	-8.8pp

CARM underperformed the S&P 500 by 121.21pp over the past year (-96.22% vs +24.99%).

Loading summary...

CARM Peers' Total Return

Accurate peer set · 10 comparable names

Name	Mkt Cap	30D Rtn	YTD Total Rtn	1Y Total Rtn	Div Contrib	3Y Total Rtn	5Y Total Rtn	10Y Total Rtn
CARMCarisma Therapeutics, Inc.	$795,056	+18900.0%	-56.8%	-96.2%	—	-99.8%	-99.6%	-99.1%
MGTXMeiraGTx Holdings plc	$1.0B	+20.4%	+44.9%	+74.7%	—	+54.0%	-26.3%	-24.5%
FATEFate Therapeutics, Inc.	$244M	+20.8%	+111.1%	+72.7%	—	-64.4%	-97.4%	+4.5%
SANASana Biotechnology, Inc.	$877M	+3.6%	-24.8%	+14.1%	—	-49.1%	-86.0%	-91.0%
BEAMBeam Therapeutics Inc.	$3.5B	+27.3%	+25.8%	+100.9%	—	+2.4%	-59.8%	+82.1%
NTLAIntellia Therapeutics, Inc.	$1.8B	+23.5%	+70.1%	+63.2%	—	-64.1%	-79.4%	-43.2%
CRSPCRISPR Therapeutics AG	$5.2B	+11.4%	+0.6%	+21.7%	—	-4.9%	-57.7%	+283.9%
KYMRKymera Therapeutics, Inc.	$7.4B	+13.5%	+24.3%	+94.7%	—	+259.0%	+91.0%	+171.9%
ALNYAlnylam Pharmaceuticals, Inc.	$37.1B	-2.9%	-30.5%	-11.0%	—	+37.9%	+57.2%	+391.0%
EDITEditas Medicine, Inc.	$263M	+6.3%	+31.2%	+14.5%	—	-67.8%	-92.5%	-90.9%
ILMNIllumina, Inc.	$24.6B	+14.4%	+20.5%	+79.4%	—	-17.6%	-63.5%	+18.9%

Compare:CARM vs MGTX CARM vs FATE CARM vs SANA CARM vs MGTX vs FATE

About CARM Dividend Returns

Carisma Therapeutics, Inc. (CARM) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends.

How We Calculate Total Return

Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.

Frequently Asked Questions

Q1What is the total return of CARM over the past year?

Carisma Therapeutics, Inc. (CARM) delivered a return of -96.22% over the past year. Since CARM does not currently pay dividends, the total return equals the price-only return.

Q2How much would $10,000 invested in CARM be worth today?

A $10,000 investment in Carisma Therapeutics, Inc. one year ago would be worth $378 today, representing a loss of $9,622.

Q3Does CARM pay dividends?

Carisma Therapeutics, Inc. (CARM) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For CARM, the total return equals the price-only return.

Q4Did CARM beat the S&P 500?

No, Carisma Therapeutics, Inc. (CARM) underperformed the S&P 500 by 121.21 percentage points over the past year. CARM delivered a total return of -96.22%, compared to the S&P 500's 24.99%. This means a passive S&P 500 index fund outperformed CARM by 121.21pp during this period.

Q5What is CARM's worst drawdown?

Carisma Therapeutics, Inc. (CARM) experienced a maximum drawdown of -99.98% over the past year, declining from its peak on 2025-06-18 to its trough on 2026-05-14. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Q6What is CARM's long-term total return over 10, 20, or 30 years?

Here are Carisma Therapeutics, Inc. (CARM)'s long-term returns with dividends reinvested. Over 10 years, the total return is -99.1% (-37.9% CAGR) — $10,000 would have grown to $86. Over 20 years: -99.8% total return (-27.2% CAGR) — $10,000 → $18. Over 30 years: -99.8% total return (-19.1% CAGR) — $10,000 → $18. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Q7What was CARM's best and worst year?

Carisma Therapeutics, Inc.'s best calendar year was 2018 with a total return of 71.1%. Its worst year was 2025 with a total return of -90.2%. This range shows the volatility investors should expect — the difference between the best and worst year is 161.3 percentage points.

How much would $100/month in CARM be worth today?

Dollar cost averaging calculator · DCA vs lump sum · see how regular investing compounds

Run the Numbers →